2025年2月9日，据CDE官网公示，信达生物已递交其1类新药IBI115的临床试验（IND）申请。 据公开资料，IBI115 是一款DLL3/CD3双特异 ...

We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...

Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Molecular Partners announced positive IND-enabling data for MP0712 and preclinical findings for novel targeted Radio-DARPins at AACR 2025. Molecular Partners AG announced positive IND-enabling data ...

DUBLIN--(BUSINESS WIRE)--The "DLL3 Targeted Therapies Market, Approved Drugs, Dosage, Pricing & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com's offering. Delta-like ...

“This study presents an observational, cross-sectional analysis of 64 patients diagnosed with small cell lung cancer (SCLC) at a reference laboratory for thoracic pathology between 2022 and 2024.” ...

Tarlatamab-dlle significantly improves overall survival in SCLC compared to standard chemotherapy, as demonstrated in the phase 3 DeLLphi-304 trial. The bispecific T-cell engager targets DLL3 on tumor ...

A new imaging technique developed at Memorial Sloan Kettering Cancer Center (MSK) shows promise for detecting deadly forms of lung cancer and prostate cancer. The technology uses a radioactive ...